With your own knowledge and the help of the following document:

Document 1 (Title: Adverse Effects of Topical Nasal Decongestant Overuse): Topical nasal decongestants, including oxymetazoline, phenylephrine, and xylometazoline, provide rapid, effective relief of nasal congestion through their alpha-adrenergic agonist properties causing vasoconstriction of the nasal mucosal blood vessels. While these agents demonstrate excellent efficacy for short-term management of nasal congestion from various etiologies, their use beyond 3-5 consecutive days can lead to a paradoxical condition known as rhinitis medicamentosa. This iatrogenic form of rhinitis develops through a complex pathophysiological process involving both neurological and vascular mechanisms. The primary mechanism involves down-regulation and desensitization of alpha-adrenergic receptors in the nasal mucosa due to continuous exposure to exogenous sympathomimetics. This receptor desensitization leads to rebound vasodilation when the medication effect wanes, producing congestion that exceeds the pre-treatment state. Accompanying histopathological changes include chronic inflammation, epithelial metaplasia, and mucosal edema, which further compound the congestive symptoms. The cardinal clinical manifestation is persistent nasal congestion, most pronounced immediately after the decongestant effect subsides, creating a cycle of increasingly frequent administration. Unlike allergic rhinitis, sneezing and rhinorrhea are typically absent or minimal. The condition rarely progresses to permanent alteration of nasal architecture or irreversible olfactory dysfunction, though prolonged cases may temporarily impact smell through mechanical obstruction. Similarly, epistaxis occurs in only a minority of cases, typically related to mucosal dryness and microtrauma from the applicator. Management focuses primarily on discontinuation of the offending agent, often requiring a tapering schedule and temporary use of intranasal corticosteroids to mitigate withdrawal symptoms.
Document 2 (Title: Coagulation Defects in Young Women with Menorrhagia): Menorrhagia, defined as excessive menstrual bleeding lasting more than 7 days or exceeding 80 mL per cycle, affects approximately 10-30% of women of reproductive age, with a significant proportion attributable to underlying bleeding disorders. When persistent since menarche and accompanied by other mucocutaneous bleeding manifestations, inherited coagulation disorders warrant particular consideration. Von Willebrand disease (VWD), the most common inherited bleeding disorder, affects approximately 1% of the general population and accounts for up to 20% of unexplained menorrhagia cases in otherwise healthy women. VWD results from quantitative or qualitative deficiencies in von Willebrand factor (VWF), a large multimeric glycoprotein that mediates platelet adhesion to subendothelial collagen and serves as a carrier for factor VIII. This autosomal inheritance pattern leads to equal sex distribution, contrasting with the X-linked recessive inheritance of hemophilia A, which primarily affects males. Laboratory evaluation of VWD typically reveals prolonged activated partial thromboplastin time (aPTT) due to secondary factor VIII deficiency, while prothrombin time (PT) and platelet count remain normal. Patients typically present with mucocutaneous bleeding manifestations including easy bruising, epistaxis, gingival bleeding, and particularly menorrhagia in women. Family history often reveals similar bleeding tendencies in first-degree relatives of both sexes, contrasting with the maternal uncle pattern in hemophilia A or the prothrombotic tendencies in conditions like protein C deficiency or antiphospholipid syndrome.
Document 3 (Title: Contemporary Management of Necrotizing Perineal Infections): Fournier's gangrene represents a particularly aggressive form of necrotizing fasciitis involving the perineal, genital, and perianal regions that continues to carry significant mortality despite modern medical advances. Epidemiological analysis demonstrates persistently high mortality rates ranging from 20-30% in contemporary series despite aggressive multidisciplinary management. Multiple institutional reviews document the rapid progression potential, with tissue destruction advancing at rates exceeding 2-3 cm per hour during active infection phases. Microbiological assessment consistently reveals polymicrobial infections with synergistic virulence factors that accelerate tissue necrosis through enhanced enzymatic activity and toxin production. Systematic reviews of prognostic factors demonstrate that delayed diagnosis and surgical intervention correlate directly with increased mortality, with each 6-hour delay associated with a 7-9% increase in mortality risk across multiple studies. Modern intensive care capabilities, while significantly improved, have not eliminated the lethal potential of this condition when diagnosis or intervention is delayed. Immunocompromised states, including diabetes mellitus and chronic alcohol use, significantly increase both susceptibility and complication rates, with mortality approaching 40% in these high-risk groups. The condition's anatomical location facilitates rapid spread through interconnected fascial planes while often masking early clinical signs, delaying presentation and diagnosis. Validated severity scoring systems continue to document substantial mortality risk even with optimal contemporary management. These collective findings from modern clinical series demonstrate that despite significant advances in surgical techniques, antimicrobial therapy, and critical care support, Fournier's gangrene remains a condition with substantial lethal potential requiring the highest level of clinical vigilance and aggressive multidisciplinary intervention.

Answer the following multiple-choice question.
Question: A 35-year-old male presents to his primary care physician with complaints of seasonal allergies. He has been using intranasal vasoconstrictors several times per day for several weeks. What is a likely sequela of the chronic use of topical nasal decongestants?
Options:
A. Epistaxis
B. Permanent loss of smell
C. Persistent nasal crusting
D. Persistent congestion

Respond strictly in valid JSON format as follows:
{"answer_choice": "A"} ‚Üê if A is the answer
Output only the JSON object. Do not include any explanation, commentary, markdown, or extra text.